Guggenheim Maintains Buy on Tenet Healthcare, Lowers Price Target to $242

Benzinga Newsdesk www.benzinga.com Neutral 48.4%

Neg 0% Neu 48.4% Pos 0%

Guggenheim analyst Jason Cassorla maintains Tenet Healthcare (NYSE:THC) with a Buy and lowers the price target from $252 to $242.